statistiche ricercatore

CLEMENTI, MASSIMO

Distribuzione geografica

Continente	#
NA - Nord America	2.254
AS - Asia	1.648
EU - Europa	1.641
SA - Sud America	170
AF - Africa	31
OC - Oceania	5
Totale	5.749

Salva come PNG Salva come JPEG

Nazione	#
US - Stati Uniti d'America	2.170
IT - Italia	1.031
SG - Singapore	707
CN - Cina	404
HK - Hong Kong	253
BR - Brasile	150
VN - Vietnam	128
GB - Regno Unito	110
FR - Francia	91
DE - Germania	89
FI - Finlandia	81
IE - Irlanda	76
RU - Federazione Russa	75
CA - Canada	41
IN - India	37
MX - Messico	37
BD - Bangladesh	25
JP - Giappone	19
NL - Olanda	14
PL - Polonia	14
ES - Italia	11
IQ - Iraq	11
TR - Turchia	11
AT - Austria	10
SA - Arabia Saudita	10
KE - Kenya	8
ZA - Sudafrica	8
AR - Argentina	7
BE - Belgio	7
LT - Lituania	6
NG - Nigeria	6
CH - Svizzera	5
AE - Emirati Arabi Uniti	4
AU - Australia	4
JO - Giordania	4
MD - Moldavia	4
SE - Svezia	4
UA - Ucraina	4
AZ - Azerbaigian	3
MA - Marocco	3
PK - Pakistan	3
UZ - Uzbekistan	3
BG - Bulgaria	2
CL - Cile	2
CO - Colombia	2
CR - Costa Rica	2
DK - Danimarca	2
EC - Ecuador	2
EG - Egitto	2
GE - Georgia	2
ID - Indonesia	2
IL - Israele	2
KR - Corea	2
KZ - Kazakistan	2
LB - Libano	2
PE - Perù	2
PH - Filippine	2
QA - Qatar	2
VE - Venezuela	2
BH - Bahrain	1
BO - Bolivia	1
BY - Bielorussia	1
BZ - Belize	1
CG - Congo	1
CI - Costa d'Avorio	1
CY - Cipro	1
ET - Etiopia	1
GN - Guinea	1
GR - Grecia	1
IR - Iran	1
JM - Giamaica	1
KG - Kirghizistan	1
MM - Myanmar	1
MY - Malesia	1
NC - Nuova Caledonia	1
NP - Nepal	1
OM - Oman	1
PS - Palestinian Territory	1
PY - Paraguay	1
RS - Serbia	1
SI - Slovenia	1
SK - Slovacchia (Repubblica Slovacca)	1
SY - Repubblica araba siriana	1
TT - Trinidad e Tobago	1
UY - Uruguay	1
VC - Saint Vincent e Grenadine	1
Totale	5.749

Salva come PNG Salva come JPEG

Città	#
Milan	682
San Jose	515
Singapore	372
Ashburn	276
Hong Kong	250
Council Bluffs	206
Chicago	168
Beijing	152
The Dalles	120
Dallas	100
Boardman	86
Dublin	76
London	75
Helsinki	71
Lauterbourg	71
Los Angeles	64
Rome	61
Ho Chi Minh City	42
Hanoi	33
New York	33
Santa Clara	33
Mexico City	29
Munich	27
Washington	27
Ogden	26
Frankfurt am Main	21
Brooklyn	20
Seattle	20
Orem	18
Tokyo	18
Varese	17
San Francisco	14
Warsaw	14
Chennai	13
Como	13
Atlanta	12
Toronto	12
Shanghai	11
Guangzhou	10
Montreal	10
Nuremberg	10
São Paulo	10
Denver	8
Nairobi	8
Shenzhen	8
Vancouver	8
Vienna	8
Amsterdam	7
Boston	7
Brussels	7
Phoenix	7
Pittsburgh	7
Pune	7
Abuja	6
Ankara	6
Da Nang	6
Dhaka	6
Hangzhou	6
Johannesburg	6
New Delhi	6
Poplar	6
Berlin	5
Düsseldorf	5
Falkenstein	5
Haiphong	5
Magnago	5
Miami	5
Querétaro	5
Rio de Janeiro	5
Amman	4
Baghdad	4
Bari	4
Belo Horizonte	4
Bodio Lomnago	4
Cernusco sul Naviglio	4
Chiswick	4
Detroit	4
Houston	4
Jeddah	4
Mumbai	4
Riyadh	4
Salt Lake City	4
Sulmona	4
Turku	4
West Jordan	4
Alexandria	3
Blumenau	3
Campinas	3
Changsha	3
Fortaleza	3
Goiânia	3
Hải Dương	3
Indianapolis	3
Kunming	3
Lappeenranta	3
Manchester	3
Memphis	3
Newark	3
Paris	3
Stockholm	3
Totale	4.117

Salva come PNG Salva come JPEG

Nome	#
A biologically-validated HCV E1E2 heterodimer structural model	121
A Human Monoclonal Antibody with Neutralizing Activity against Highly Divergent Influenza Subtypes	116
High Risk of Secondary Infections Following Thrombotic Complications in Patients With COVID-19	113
Analysis of the faecal microbiome during analytical treatment interruption in people with chronic HIV infection and long-lasting virological suppression (APACHE study)	113
Nanopore ReCappable sequencing maps SARS-CoV-2 5' capping sites and provides new insights into the structure of sgRNAs	107
Dose-Dependent Impairment of the Immune Response to the Moderna-1273 mRNA Vaccine by Mycophenolate Mofetil in Patients with Rheumatic and Autoimmune Liver Diseases	105
Clinical characterization and whole genome sequence-based typing of two cases of endophthalmitis due to Listeria monocytogenes	104
Broadly neutralizing anti-influenza human monoclonal antibodies and their possible role in predictive medicine	104
Adjuvant role of SeptiFast to improve the diagnosis of sepsis in a large cohort of hematological patients	104
Mechanisms of Hepatitis C Virus Escape from Vaccine-Relevant Neutralizing Antibodies	103
A non-VH1-69 heterosubtypic neutralizing human monoclonal antibody protects mice against H1N1 and H5N1 viruses	102
A case of psoriatic arthritis triggered by SARS-CoV-2 infection	101
Characterization of epitopes recognized by monoclonal antibodies: experimental approaches supported by freely accessible bioinformatic tools	99
Chimeric antigen receptor (CAR)-engineered T cells redirected against hepatitis C virus (HCV) E2 glycoprotein	99
Proper Selection of In Vitro Cell Model Affects the Characterization of the Neutralizing Antibody Response against SARS-CoV-2	98
Adoptive T-cell therapy in the treatment of viral and opportunistic fungal infections	98
Molecular diagnosis of sepsis in neutropenic patients with haematological malignancies	94
Novel therapeutic investigational strategies to treat severe and disseminated HSV infections suggested by a deeper understanding of in vitro virus entry processes	92
Possible future monoclonal antibody (mAb)-based therapy against arbovirus infections	91
Autoimmune hepatitis and occult HCV infection: A prospective single-centre clinical study	91
Answer to photo quiz: Streptococcus pneumoniae	88
Phage display-based strategies for cloning and optimization of monoclonal antibodies directed against human pathogens	88
A human stem cell-derived neurosensory–epithelial circuitry on a chip to model herpes simplex virus reactivation	86
The interferon landscape along the respiratory tract impacts the severity of COVID-19	86
Differential composition of vaginal microbiome, but not of seminal microbiome, is associated with successful intrauterine insemination in couples with idiopathic infertility: A prospective observational study	85
Neutralization Interfering Antibodies: a "Novel" Mechanism of Humoral Immune Mutiny and Viral Evasion?	84
Molecular characterization of the human neutralizing response against hepatitis C virus and its role in the prediction of the infection outcome	83
Anti-hepatitis C virus E2 (HCV/E2) glycoprotein monoclonal antibodies and neutralization interference	83
Identification of a novel mutation involved in colistin resistance in Klebsiella pneumoniae through Next-Generation Sequencing (NGS) based approaches	83
JC polyomavirus (JCV) and monoclonal antibodies: friends or potential foes?	82
Combined prophylactic and therapeutic use maximizes hydroxychloroquine anti-SARS-CoV-2 effects in vitro	81
Cell-to-cell spread-blocking activity is extremely limited in the sera of HSV-1 and HSV-2 infected subjects	80
Heterosubtypic protection conferred by the human monoclonal antibody PN-SIA28 against influenza A virus lethal infections in mice	77
Fast inactivation of SARS-CoV-2 by UV-C and ozone exposure on different materials	77
Lower nasopharyngeal viral load during the latest phase of COVID-19 pandemic in a Northern Italy University Hospital	77
Molecular signatures of hepatitis C virus (HCV)-induced type II mixed cryoglobulinemia (MCII)	76
Viral respiratory pathogens and lung Injury	76
Microbiome markers are early predictors of acute GvHD in allogeneic hematopoietic stem cell transplant recipients	75
Enteric microbiome markers as early predictors of clinical outcome in allogeneic hematopoietic stem cell transplant (allo-HSCT): results of a prospective study in adult patients	73
Chimeric antigen receptor (CAR)-redirected T cells: is there a place for them in infectious diseases?	72
Risks of "blind" automated identification systems in medical microbiology	72
Hepatitis C virus (HCV) infection may elicit neutralizing antibodies targeting epitopes conserved in all viral genotypes	71
IFCC interim guidelines on molecular testing of SARS-CoV-2 infection	71
Early molecular diagnosis of aspergillosis in a patient with acute myeloid leukaemia	70
Weak correlation between antibody titers and neutralizing activity in sera from SARS-CoV-2 infected subjects	70
Very high SARS-CoV-2 load at the emergency department presentation strongly predicts the risk of admission to the intensive care unit and death	70
Cloning of the first human anti-JCPyV/VP1 neutralizing monoclonal antibody: Epitope definition and implications in risk stratification of patients under natalizumab therapy	67
Characterization of two human monoclonal anti-E2/HCV antibodies for potential application in prevention and treatment of HCV infection	67
Virus-induced preferential antibody gene-usage and its importance in humoral autoimmunity	66
Characterization of four major human B-cell epitopes on the surface of HCV E2 glycoprotein by generation of human monoclonal Fab from phage display antibody librariesis	64
HCV Proteins and Immunoglobulin Variable Gene (IgV) Subfamilies in HCV-Induced Type II Mixed Cryoglobulinemia: A Concurrent Pathogenetic Role	64
Structural and antigenic definition of hepatitis C virus E2 glycoprotein epitopes targeted by monoclonal antibodies	64
Divergent Trends of Anti-JCPyV Serum Reactivity and Neutralizing Activity in Multiple Sclerosis (MS) Patients during Treatment with Natalizumab	62
Diverging effects of human recombinant anti-hepatitis C virus (HCV) antibody fragments derived from a single patient on the infectivity of a vesicular stomatitis Virus/HCV pseudotype	62
Influenza B-cells protective epitope characterization: a passkey for the rational design of new broad-range anti-influenza vaccines	59
Role and potential therapeutic use of antibodies against herpetic infections	59
Synergy evaluation of anti-Herpes Simplex Virus type 1 and 2 compounds acting on different steps of virus life cycle	58
Entry inhibition of HSV-1 and -2 protects mice from viral lethal challenge	57
Modulation of epitope-specific anti-hepatitis C virus E2 (Anti-HCV/E2) antibodies by anti-viral treatment	56
IFCC interim guidelines on biochemical/hematological monitoring of COVID-19 patients	55
Heparin Inhibits Cellular Invasion by SARS-CoV-2: Structural Dependence of the Interaction of the Spike S1 Receptor-Binding Domain with Heparin	54
Differential plasmacytoid dendritic cell phenotype and type I Interferon response in asymptomatic and severe COVID-19 infection	54
Anti-HIV-1 response elicited in rabbits by anti-idiotype monoclonal antibodies mimicking the CD4-binding site on gp120SITE ON GP120	53
Human Monoclonal Antibody able to nneutralize a broad range of H1 and H3 subtype influenza A viruses	50
Perspectives for the utilization of neutralizing human monoclonal antibodies as anti-HCV drugs	49
Interferon β-1a (IFNβ-1a) in COVID-19 patients (INTERCOP): study protocol for a randomized controlled trial	49
Photo quiz: Neurological symptoms in a 74-year-old diabetic woman admitted to the emergency room	48
Microbiological Diagnosis of Sepsis: The Confounding Effects of a “Gold Standard”	46
Facing the Rising Tide of Multidrug Resistant Gram-Negative Pathogens in Allogeneic HSCT with Nanosphere's Verigene((R)) System	45
Nanosphere's Verigene (R) System to detect Multidrug-Resistant Gram-negative Bacterial Outbreak: a prospective study in 60 patients	45
Longitudinal microbiome profile associates with the risk of major transplant-related complications in allogeneic HSCT recipients	45
Molecular dissection of the IGM/K antibody repertoire in an HCV-infected patient with cryoglobulinemia	44
Molecular Cloning of a Human Monoclonal Antibody neutralizing a broad range of H1 subtype influenza virus including swine-origin influenza virus (S-OIV)	44
Rapid Molecular Detection of Pathogens in 516 Consecutive Haematological Patients with Febrile Neutropenia	43
Oral and Fecal Microbiota in Lynch Syndrome	42
Rational dosing strategies of colistin: what about resistance?	40
Definition of biological activity and quantitation of different families of human anti-HCV/E2 antibodies by generation of human recombinant anti-E2 monoclonal Fab by phage display combinatorial repertoire library	40
Molecular dissection of the human humoral response against HCV E2 glycoprotein by cloning of the antibody repertoire in phage display combinatorial vectors	39
Evaluation of a synergistic interactions of anti-E2/HCV monoclonal antibodies	38
Improving the Diagnostic Algorithm for Sepsis: Adjuvant Role of SeptiFast in 491 Consecutive Hematological Patients	38
RAPID MOLECULAR DETECTION OF PATHOGENS IN 1941 BLOOD SAMPLES FROM 516 CONSECUTIVE PATIENTS WITH FEBRILE NEUTROPENIA	35
Molecular Diagnosis of Scedosporium apiospermum Keratitis	33
Multiplex PCR-based assay (SeptiFast) for rapid detection of pathogens in febrile neutropenia: results in 273 consecutive patients	32
Totale	5.957

Salva come PNG Salva come JPEG

Categoria	#
all - tutte	33.540
article - articoli	0
book - libri	0
conference - conferenze	0
curatela - curatele	0
other - altro	0
patent - brevetti	0
selected - selezionate	0
volume - volumi	0
Totale	33.540

Salva come PNG Salva come JPEG

	Totale	Lug	Ago	Sett	Ott	Nov	Dic	Gen	Feb	Mar	Apr	Mag	Giu
2022/2023	232	0	0	0	0	0	0	0	0	123	71	20	18
2023/2024	1.288	163	195	164	256	300	87	7	25	35	35	9	12
2024/2025	1.248	9	38	262	62	46	68	55	57	155	75	92	329
2025/2026	3.157	288	168	156	390	203	125	717	157	433	205	165	150
2026/2027	32	32	0	0	0	0	0	0	0	0	0	0	0
Totale													5.957